Department of Stem Cell Transplantation and Cell Therapy, MD Anderson Cancer Center, Houston, TX, USA
Lung stem cell transplantation for pulmonary fibrosis
Host: L. Braga
Abstract
Despite the emergence of novel compounds for the treatment of Idiopathic Pulmonary Fibrosis (IPF), lung transplantation remains the only “curative” option, albeit with a low 5-year mean survival rate following transplantation. This lack of treatment options highlights the urgent need for novel therapies, with special emphasis on emerging approaches for transplantation of lung stem cells. Very recently we demonstrated in two distinct mouse models of pulmonary fibrosis that intravenous infusion of multi-potent lung progenitors, present in single cell lung suspensions, home to the lung and induce robust regeneration of donor derived AT1 and AT2 alveolar, mesenchymal and endothelial cells. This lung chimerism is associated with attenuation of fibrosis, as demonstrated histologically, biochemically, by CT imaging, and by lung function measurements. Our plans for a first-in -human phase 1-2 clinical trial, evaluating the safety and tolerability of cadaveric lung cell infusion in IPF patients will be discussed .
International Seminar Programme
Hundreds of videos, tens of playlists providing free scientific content worldwide
